Results 241 to 249 of about 27,256 (249)

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

Diabetologia, 2016
Mark M Smits, Lennart Tonneijck, Marcel H A Muskiet   +2 more
exaly  

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

Journal of Clinical Endocrinology and Metabolism, 2006
Carolyn F Deacon
exaly  

Sitagliptin

Reactions Weekly, 2016
openaire   +1 more source

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

Diabetologia, 2013
exaly  

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

Diabetologia, 2006
exaly  

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

Diabetes, Obesity and Metabolism, 2007
exaly  

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

Diabetes, Obesity and Metabolism, 2007
exaly  

Sitagliptin: A Review in Type 2 Diabetes

Drugs, 2017
exaly  

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

Diabetes, Obesity and Metabolism, 2010
exaly